Tagged with Alzheimer's Disease

Aducanumab edges closer to Potential Approval: Next up, the Advisory Committee meeting

USA Aducanumab edges closer to Potential Approval: Next up, the Advisory Committee meeting

USA In his latest piece on Alzheimer’s Disease (AD) drug Aducanumab’s winding journey to market, Dr Neil Cashman looks forward to the US FDA Advisory Committee’s meeting on November 6 2020, what it means for that Aducanumab, and the impact on next-generation AD treatments. November 6 could prove to be…

Aducanumab: On the Regulatory Home Stretch in the USA

Opinion Aducanumab: On the Regulatory Home Stretch in the USA

Opinion In the third of a series of articles chronicling Biogen/Eisai’s Alzheimer’s Disease (AD) treatment aducanumab’s torturous journey to market, Dr Neil Cashman highlights what the next steps in the process will be, why US FDA approval for the drug will pave the way for researchers working on second-generation AD medicines,…

Ivan Cheung – Chairman, Eisai Inc.; President, Neurology Business Group, Eisai Co., Ltd.

USA Ivan Cheung – Chairman, Eisai Inc.; President, Neurology Business Group, Eisai Co., Ltd.

USA Ivan Cheung, head of Japanese firm Eisai’s US operations, highlights the significance of a potential 2021 US FDA approval for Alzheimer’s Disease drug aducanumab, developed in collaboration with Biogen. Cheung also compares the differing challenges of the oncology and neuroscience markets and outlines the unique Eisai company culture. We…